Research that Identifies
Undiscovered Value in the MicroCap Market


Trxade Group Email List: Click to Subscribe

View Company Website: Click to View

Market Data: Yahoo Finance, SEC Filings, Bloomberg

Report Link: Updated Research Report (Dated 07/30/2020)

Symbol: MEDS
Analyst: Howard Halpern
Taglich Rating: Speculative Buy
Price Target: $10.50
Time Horizon: 12 Months
Rating Established: June 10, 2020
Price When Established: $6.12
Most Recent Report: July 30, 2020
Price When Issued: $7.54

What's New

Trxade Launches Bonum+ B2B Platform

On August 11, 2020, Trxade Group, Inc. announced its Bonum Health subsidiary launched a Business-to-Business platform called Bonum+. This platform bundles telehealth, a COVID-19 risk assessment tool, and a personal protective equipment purchasing tool, through a secure mobile dashboard for corporate clients.

The aim of this new offering is to ease pressure on employees who are required to report any relevant health issues daily, allows employers to monitor employee COVID-19 risk profiles, as well as streamlining the ordering of new personal protective equipment.

Company Description

Trxade Group Inc., headquartered in Tampa, Florida, is an integrated technology and services company focused on delivering an effective process for purchasing and delivering prescription drugs to independent pharmacies and consumers in the US. MEDS is developing a complete platform to make healthcare services affordable and accessible in the US through the integration of its existing Web-based trading platform, a licensed wholesaler, and its mobile telehealth service through the Bonum Health app and delivery capabilities. The company is developing the ability to provide healthcare services to patients without the patient leaving their home.

Company Reports

Updated Research Report (Dated 07/30/2020)
Initial Research Report (Dated 06/10/2020)


Please view our current disclosure and disclaimer on our most recent research report.